Carisma Therapeutics Inc.
CFO
2023-03-07–present
CFO
Carisma Therapeutics Inc.
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Richard Morris is recorded as CFO at Carisma Therapeutics Inc.. Carisma Therapeutics Inc. reported in an 8-K filed December 9, 2024 that Richard Morris was terminated as Chief Financial Officer, effective December 31, 2024. Carisma Therapeutics Inc. reported in an 8-K filed March 8, 2023 that Richard Morris was appointed Chief Financial Officer, Chief Compliance Officer and Treasurer, principal financial officer and principal accounting officer, effective March 7, 2023.
“On December 7, 2024, as part of the reduction in workforce, the Company notified Richard Morris, the Company's Chief Financial Officer, that his employment with the Company will terminate without cause effective December 31, 2024.”
“Effective as of the effective time of the Merger, the Board appointed Steven Kelly as the Company's President and Chief Executive Officer and principal executive officer, Richard Morris as the Company's Chief Financial Officer, Chief Compliance Officer and Treasurer, principal financial officer and principal accounting officer and Michael Klichinsky, Pharm.D., Ph.D. as Chief Scientific Officer, each to serve at the discretion of the Board.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
Carisma Therapeutics Inc.
CFO
SEC 8-K
2023-03-07–present
Carisma Therapeutics Inc.
CFO
Proxy statement
2023-03-07–2024-12-31
Carisma Therapeutics Inc.
CFO
Proxy statement
Start not stated–2024-12-31
Recorded roles and call appearances connecting this person to public companies.
Carisma Therapeutics Inc.
CFO
2023-03-07–present
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
Carisma Therapeutics Inc.